PLATFORM
Three enabling platforms.
Two therapeutic directions.
One integrated development system.
- In vivo CAR-T: cmCAR circular mRNA and cell-selective CellectLNP delivery support transient, non-integrating immune-cell programming in vivo.
- AI-native personalized neoantigen cancer vaccine (PCV): Neodiscovery.ai ranks and optimizes patient-specific neoantigen combinations for BR202.
- Integrated translation: In-house CMC, analytics and manufacturing connect design choices with product quality and delivery across both programs.
Closed topology is designed to support intracellular RNA stability; expression magnitude and duration remain dependent on construct design, delivery, dose and biological context.
BYTERNA cmRNA · RNA ARCHITECTURE
Circular mRNA designed as a programmable expression system.
Byterna cmRNA combines a scarless-style covalently closed RNA backbone with a highly structured internal ribosome entry site (IRES) and a program-specific coding sequence (CDS). The architecture is designed to support cap-independent translation and program-specific expression. Circularization, identity, purity, expression kinetics, molecular stability and manufacturability are evaluated together for each construct.
01 Covalently closed, modular architecture02 Program-specific expression design03 Quality- and manufacturability-aware development
- Design principle
- A covalently closed, modular RNA architecture.
- What is engineered
- IRES structure, program-specific CDS and construct junction.
- What is measured
- Circularization, identity, purity, expression kinetics, molecular stability and manufacturability.
- Program application
- Shared RNA foundation for BR101 in vivo CAR-T and BR202 personalized cancer vaccines.
- Evidence status
- Platform design objective; construct-specific performance is established experimentally.
TARGETED DELIVERY
CellectLNP
Delivery
CellectLNP is designed to couple antibody-directed binding with receptor-mediated uptake in selected immune cells. Development focuses on conjugation chemistry, biodistribution, endosomal escape, cytosolic cmRNA release, intended-cell expression, tolerability and manufacturability.
01 Antibody-directed cell targeting02 Extra-hepatic biodistribution03 Intended-cell expression
- Design principle
- Antibody-directed binding coupled to receptor-mediated uptake.
- What is engineered
- Conjugation chemistry, particle properties and targeting-ligand presentation.
- What is measured
- Biodistribution, uptake, endosomal escape, cytosolic release, expression and tolerability.
- Program application
- Cell-selective circular mRNA delivery for the in vivo CAR-T portfolio.
- Evidence status
- Preclinical delivery-system development.
- Biodistribution
- Target-cell binding
- Uptake
- Endosomal escape
- cmRNA release
- CAR expression
Conceptual illustration of the intended design and mechanism; not to scale.
PERSONALIZED NEOANTIGEN VACCINE DESIGN
Neodiscovery.ai
A traceable design system for patient-specific neoantigen combinations.
For BR202, Neodiscovery.ai integrates matched tumor-normal sequencing, tumor expression and HLA context to generate, rank and experimentally review combinations of patient-specific neoantigens. Candidate selection is treated as a testable design hypothesis, with evidence and manufacturing constraints recorded at each decision gate.
- Design principle
- Evidence-weighted, patient-specific neoantigen selection.
- What is engineered
- Candidate-generation, ranking and construct-selection workflow.
- What is measured
- Presentation evidence, immunogenicity, clonality, experimental validation and manufacturability.
- Program application
- Patient-specific antigen-set selection and circular mRNA design for BR202.
- Evidence status
- Preclinical design system; model outputs are hypotheses for experimental review.
Illustrative workflow—not benchmark or clinical performance data.